A recent review [10] and a meta-analysis [12] have both examined various biomarkers in MS-related NI across the disease’s progression, emphasizing NfL, particularly in the CSF, as a robust indicator of effects on the CNS. This evidence concerns the gene NEFL and myeloid sarcoma.